Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1484-2026

Atellica CH Urine Albumin (UAlb). Material Number: 11537225 Recall

Atellica CH Urine Albumin (UAlb). Material Number: 11537225

FDA recall Class II

Ongoing

FDA lists this Class II recall for Atellica CH Urine Albumin (UAlb). Material Number: 11537225. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1484-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Jan 20, 2026
FDA report date
Mar 11, 2026
Quantity in commerce
4,885 units
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Atellica CH Urine Albumin (UAlb). Material Number: 11537225

Affected model & UDI checker

Search the exact identifiers published for Z-1484-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
Not specifiedAtellica CH Urine Albumin (UAlb). Material Number: 11537225Check source notice00630414611099
FDA code information

Material Number: 11537225. UDI-DI: 00630414611099. Lot Numbers: All lot numbers.

View the original FDA recall notice

Why was this product recalled?

Falsely depressed UAlb patient results may occur. Affected samples with any urine albumin concentration above the UAlb measuring interval >40.0 mg/dL may report values between 6.2 mg/dL and 40.0 mg/dL.

What actions did Siemens Healthcare Diagnostics, Inc. take?

Siemens Healthineers notified consignees on about 01/20/2026 via mailed FedEx letter titled Urgent Medical Device Correction. Consignees were informed that as temporary mitigation, for any sample with a UAlb result above 5.0 mg/dL (50 mg/L), reanalyze the sample with a x10 dilution. If the diluted result is consistent with the initial result, either result may be reported. If the diluted result is inconsistent with the initial result, the diluted result should be reported. If you prefer to automate this dilution, please refer to your internal laboratory procedures. Consignees were instructed to review the notification with their Medical Director to determine the appropriate course of action, including evaluation of any previously generated results, if applicable, and complete and return the provided Field Correction Effectiveness Check Form. A follow-up communication will be provided when Customer Actions are no longer required.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology